Ariad Pharmaceuticals reported that it has entered a nonexclusive license agreement with Icon Medical to develop drug-eluting stents that deliver Ariad's mTOR inhibitor, deforolimus, to prevent restenosis of injured vessels following angioplasty /stenting.
Browse by Speciality Area